| (Values in U.S. Thousands) | Jan, 2026 | Jan, 2026 | Jan, 2026 | Jan, 2026 | Jan, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Mount Rainier Acquisition Corp (RNER)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
RainEarth Inc was incorporated in the State of Nevada on March 14, 2006 under the name of Gold Rock Resources Inc. On March 27, 2009, the Company changed its name to RainEarth Inc. It is a developing stage company and seeking new business opportunities. The Company would provide Advice and assistance relating to development of marketing and provision of consultancy services, particularly as related to the Business to China RainEarth. China RainEarth will retain the services of the Company in relation to the current and proposed operations of China RainEarth's business in the People's Republic of China. Competition among pharmaceutical and other companies that develop, manufacture or market pharmaceutical products, including blood dialysis, is intense. The Company competes with these entities in all areas of business, including competing to attract and retain qualified scientific and technical personnel. China RainEarth relies on trade secrets, unpatented proprietary know-how, continuing technological innovation and patent protection to preserve its competitive position.